Invest in Arcus Biosciences for a strong buying opportunity with promising data, robust pipeline, and significant market ...

Precision BioSciences gains momentum as iECURE reports positive ECUR-506 data, and analysts forecast significant HBV ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Last month Arcus reported top -line phase 2 results with the TIGIT drug that it said warranted taking it forward into a phase 3 programme, but so far there's no word from Gilead on a buy-in.

Long term Arcus Biosciences, Inc. (NYSE:RCUS) shareholders know that all too well, since the share price is down considerably over three years. Unfortunately, they have held through a 65% decline ...

However, for Arcus Biosciences (RCUS), low expectations for its anti-TIGIT in lung cancer is likely already priced into the stock, the analyst tells investors in a research note. Barclays believes ...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies ...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...

HAYWARD, Calif., December 19, 2024--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and ...

Zimberelimab is under clinical development by Arcus Biosciences and currently in Phase II for Pancreatic Ductal Adenocarcinoma.

Marcus Rashford has set Barcelona a deadline to finalise terms as he looks to secure a Manchester United exit, ...